Photo by Dan Galvani Sommavilla on Pexels

Mindstate Design Labs, a startup funded by Silicon Valley investors, has announced the creation of a unique compound developed with the aid of artificial intelligence. Described as offering the therapeutic potential of psychedelics without the associated hallucinogenic effects, the compound aims to provide benefits similar to traditional psychedelics but with a significantly reduced, or absent, altered state of consciousness. This novel approach leverages AI to target specific neurological pathways, potentially revolutionizing mental health treatment.